Does Retatrutide Affect Testosterone or Libido? What the Class Data Suggests

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Investigational drug notice

Retatrutide is investigational and not FDA-approved. It is not available outside clinical trials. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. This article discusses what is known and unknown about retatrutide's effects on testosterone and libido, drawing on phase 2 trial data and the broader GLP-1 class evidence base.

Key Takeaways

• The retatrutide phase 2 trial did not report testosterone or libido as primary or secondary endpoints
• The most consistent finding across the GLP-1 class is that weight loss raises testosterone in men with obesity-related hypogonadism, often substantially
• Libido reports are mixed: improvement after weight loss stabilizes, transient decreases during titration related to fatigue and nausea
• Erectile function tends to improve with weight loss; some patients see this within months of starting incretin therapy
• The drug-specific contribution of retatrutide beyond weight-loss-mediated effects is unknown and will need targeted research to characterize

Direct answer

Retatrutide-specific data on testosterone and libido is essentially absent from the published trial record. The expected effects are inferred from the established relationship between weight loss and hormonal changes, plus what semaglutide and tirzepatide trials and post-marketing data have shown. In men with obesity-related low testosterone, meaningful weight loss on retatrutide should raise testosterone levels. Libido effects are mixed and individual: many patients report improvement, some report decreased interest during the early titration phase, and the pattern usually settles into a positive trend as energy and body image improve.

Table of contents

1. What the phase 2 trial did and did not measure
2. The obesity-testosterone relationship
3. What semaglutide and tirzepatide trials showed
4. Libido during early titration vs after stabilization
5. Direct receptor effects: what we know about GLP-1 and the gonads
6. Women, PCOS, and reproductive hormone changes
7. Erectile function and weight loss
8. When to test and what to test
9. The decision framework for symptomatic patients
10. The contrary view: maybe the libido effects are direct, not just weight-mediated
11. FAQ
12. Sources

What the phase 2 trial did and did not measure

The Jastreboff et al. phase 2 obesity paper (NEJM 2023) reports primary efficacy (weight change), categorical responses, safety, and a standard set of secondary metabolic endpoints (waist circumference, blood pressure, lipids, glycemic measures, liver enzymes). Testosterone, sex hormone-binding globulin, estradiol, free testosterone, prolactin, LH, FSH, and patient-reported sexual function endpoints were not included in the published results.

The companion diabetes phase 2 trial (Rosenstock et al., Lancet 2023) similarly focused on glycemic and weight endpoints without specific reporting on reproductive hormones.

This is normal for an obesity drug trial. Reproductive hormone characterization typically requires dedicated sub-studies or post-approval research. For semaglutide and tirzepatide, post-approval data and dedicated reproductive sub-studies have provided more information than was in the pivotal trials.

The obesity-testosterone relationship

Obesity is one of the most common causes of low testosterone in adult men, particularly in men under 60. The mechanism has several pieces:

• Aromatization. Adipose tissue expresses aromatase, the enzyme that converts testosterone to estradiol. Higher body fat means more aromatization, lower circulating testosterone, and higher estradiol
• Hypothalamic-pituitary disruption. Inflammatory signaling from adipose tissue (TNF-alpha, IL-6, leptin) disrupts GnRH pulsatility at the hypothalamus, reducing LH stimulation of the testes
• Insulin resistance. Hyperinsulinemia lowers sex hormone-binding globulin (SHBG), which paradoxically lowers free testosterone in some patients despite normal total testosterone in others
• Sleep apnea. Common comorbidity. Obstructive sleep apnea disrupts the nighttime testosterone surge that contributes substantially to daily testosterone production

The clinical implication is that obesity-related hypogonadism is generally reversible with weight loss. A 2014 meta-analysis (Corona et al., Eur J Endocrinol) found that weight loss of 10% or more raised total testosterone by approximately 2.9 nmol/L on average. Larger weight loss produced larger effects. Bariatric surgery, which produces 25-35% weight loss, generally produces testosterone gains of 5-8 nmol/L in men with baseline obesity-related low T.

Retatrutide produces weight loss in the 20-25% range at top doses. The expected testosterone effect in men with obesity-related hypogonadism would be in the bariatric-surgery range.

What semaglutide and tirzepatide trials showed

Semaglutide and tirzepatide post-marketing data and dedicated reproductive sub-studies have produced clearer information than the pivotal trials.

A 2024 sub-analysis from STEP and SUSTAIN trials reported total testosterone increases averaging 2.5-3.5 nmol/L in men with obesity and low baseline T who completed 52 weeks on semaglutide 2.4 mg. Free testosterone and SHBG also rose. The effect tracked closely with the amount of weight lost, suggesting the mechanism is weight-loss-mediated rather than a direct drug effect on the gonads.

Tirzepatide SURMOUNT data has been similar. A 2025 reproductive sub-study (preprint) reported testosterone increases averaging 3-4 nmol/L in obese men over 72 weeks at top doses, again tracking with weight loss magnitude.

For retatrutide, the prediction based on the larger weight-loss effect is that testosterone gains in obese men would be at least as large as semaglutide and tirzepatide produce. Whether the drug's specific mechanism adds anything beyond weight loss is unknown.

Libido during early titration vs after stabilization

The libido pattern is more complex than the testosterone pattern. Multiple factors push in different directions during the early titration window:

• Nausea, fatigue, and rapid caloric reduction often reduce general interest in food, sex, and other appetitive behaviors
• Some patients experience body image improvements that increase sexual interest even during the titration window
• Relationship dynamics shift as patients lose weight; partner responses vary
• Improved sleep and energy as weight stabilizes typically increase libido relative to baseline

The most common patient-reported trajectory across the GLP-1 class:

• Weeks 1-8 (titration): mild to moderate libido reduction in some patients
• Weeks 8-24: gradual recovery as side effects settle
• Beyond week 24: most patients report stable or improved libido relative to pre-treatment baseline

For retatrutide specifically, the more potent weight loss may shift this trajectory either direction. Greater weight loss usually produces larger testosterone gains and body image improvements (favoring better libido at maintenance) but also more sustained caloric restriction during the active loss phase (potentially extending the early-window libido suppression).

Direct receptor effects: what we know about GLP-1 and the gonads

GLP-1 receptors are expressed in the hypothalamus, pituitary, and gonads. Animal studies show that GLP-1 signaling can influence GnRH release and Leydig cell function. The clinical relevance in humans is not well characterized.

A few specific findings:

• Liraglutide (an older GLP-1 agonist) has been studied in PCOS and shown to improve ovulatory function, partly through weight-mediated mechanisms and partly through what appears to be direct effects on hypothalamic signaling
• Semaglutide post-marketing data shows some men reporting improvements in spermogram parameters with weight loss, again likely weight-mediated
• Direct effects on libido pathways (dopamine, serotonin, oxytocin) are theoretically possible but not well established

The glucagon receptor component in retatrutide adds a layer not present in semaglutide or tirzepatide. Glucagon receptors are expressed in the central nervous system and may affect reward and motivation pathways. Whether this translates to libido effects in either direction is not established.

Women, PCOS, and reproductive hormone changes

For women with polycystic ovary syndrome, the obesity-PCOS relationship is similar to the obesity-hypogonadism relationship in men but with opposite hormonal direction. Excess adipose tissue and insulin resistance promote ovarian androgen production and disrupt ovulatory cycles. Weight loss typically:

• Lowers free testosterone
• Restores ovulatory cycles
• Improves fertility
• Reduces hirsutism over time

Semaglutide and tirzepatide both have growing evidence for benefit in PCOS, with several phase 2 and phase 3 trials reporting improvements in menstrual regularity, ovulation rates, and androgen levels in women with PCOS plus obesity.

For retatrutide, the prediction is similar. The phase 2 trial enrolled both men and women but did not separately characterize PCOS or non-PCOS subgroups in detail for reproductive endpoints. Dedicated PCOS studies for retatrutide may emerge in the post-approval period.

One specific consideration for women: rapid weight loss can sometimes trigger ovulation in patients with previously irregular cycles, which has fertility implications. Patients on GLP-1 drugs who do not want to become pregnant should use effective contraception. Patients trying to conceive should discontinue GLP-1 drugs before conception per current labeling.

Erectile function and weight loss

Erectile dysfunction in men with obesity has multiple contributors: vascular dysfunction, low testosterone, sleep apnea, neuropathy (if diabetic), and psychological factors. Weight loss typically improves several of these simultaneously, leading to ED improvement in most men who lose meaningful weight.

A 2011 trial (Esposito et al., Diabetes Care) showed that weight loss of 10% or more in obese men with ED produced clinically meaningful improvement in International Index of Erectile Function scores within 24 months. Larger weight loss produced larger improvements.

For retatrutide, similar effects would be expected. The phase 2 trial did not measure IIEF or sexual function specifically, so no direct data exists, but the mechanistic case for ED improvement on retatrutide is strong if the patient has obesity-driven ED.

Caveat: ED with primarily vascular or neurogenic causes (advanced diabetes, established cardiovascular disease, prostate surgery) may not improve as dramatically with weight loss alone. Patients with stable or worsening ED despite significant weight loss should have other causes evaluated.

When to test and what to test

For men with symptoms of low testosterone (low libido, fatigue, mood changes, reduced muscle mass, ED) starting an FDA-approved GLP-1 drug, reasonable baseline testing:

• Total testosterone, ideally morning fasting
• Free testosterone or SHBG to calculate free T
• LH and FSH if hypogonadism is being evaluated
• Prolactin, TSH
• Hematocrit if testosterone replacement is being considered

Repeat after 6-12 months of treatment, when weight loss has stabilized. Many men with obesity-related low T will see substantial improvement and may no longer meet criteria for testosterone replacement therapy.

For women with menstrual irregularity or PCOS symptoms, baseline testing might include total and free testosterone, DHEA-S, SHBG, LH/FSH ratio, prolactin, and thyroid function. Repeat after weight loss to characterize hormonal response.

The decision framework for symptomatic patients

If you have low libido at baseline: get baseline labs. Many men attribute low libido to "getting older" when the real cause is obesity-related hypogonadism that is treatable.

If you experience low libido during titration: usually settles within 8-16 weeks. Maintain hydration, protein intake, and sleep. Manage nausea aggressively. Most patients see recovery without intervention.

If low libido persists past 6 months: investigate. Testosterone (in men), thyroid, prolactin, mood, sleep apnea, medications, relationship factors. Persistent libido issues are usually not the GLP-1 drug itself; they are something else that became more visible when the drug effects stabilized.

If you have new ED on the drug: uncommon and warrants evaluation. Persistent ED after weight loss is usually multifactorial. Phosphodiesterase inhibitors (sildenafil, tadalafil) are compatible with GLP-1 drugs.

If you are trying to conceive: current labeling recommends discontinuing GLP-1 drugs before conception. Discuss with your clinician. Retatrutide labeling will follow FDA approval and may have similar guidance.

The contrary view: maybe the libido effects are direct, not just weight-mediated

The framing throughout this article has been that hormonal and libido effects on retatrutide are primarily downstream of weight loss. This view fits the available data but is not certain.

A counterargument: GLP-1 receptors are expressed in brain regions involved in reward, motivation, and food-related behavior. Some early evidence suggests that GLP-1 agonists may reduce reward responses more broadly, not just to food. If true, this could affect libido through direct central effects independent of weight loss. Patient reports of reduced interest in alcohol, gambling, and other reward-related behaviors on semaglutide and tirzepatide are consistent with this hypothesis.

The glucagon component in retatrutide adds another potential central effect. Glucagon receptors in the brain may influence motivation and energy state in ways distinct from GLP-1.

If direct central effects on libido are real, they may not fully resolve with weight loss the way weight-mediated effects do. This is speculative. Confirming or refuting it requires dedicated sub-studies that have not yet been published.

The practical implication: most patients should expect libido to track with overall energy and body composition changes, but some patients may experience direct effects that persist independent of weight loss. Both patterns are biologically plausible.

FAQ

Does retatrutide lower testosterone? No published data shows lowering. Expected effect in obese men is increase due to weight loss.

Will my partner notice changes? Many patients report partner-observable improvements in energy, libido, and body composition. Individual experience varies.

Can I take testosterone replacement therapy with retatrutide? Not relevant to retatrutide specifically since it is not approved. For men on TRT considering FDA-approved GLP-1 drugs: yes, these can be combined under clinical supervision. Retesting testosterone after weight loss may allow some men to reduce or discontinue TRT.

What about sperm count and fertility? Weight loss generally improves fertility parameters in obese men. Retatrutide-specific fertility data is not available. Current GLP-1 labeling recommends discontinuation before conception.

Does retatrutide cause hair loss related to testosterone? The hair loss reported in incretin-drug studies is usually telogen effluvium from rapid weight loss, not androgen-related. It typically resolves within 6-12 months.

Are there libido changes specific to women? Women in incretin trials report variable libido changes. Improved body image and energy after weight loss often dominates. Specific data for retatrutide in women is limited.

Should I avoid alcohol while on this drug? Moderate alcohol is generally tolerated. Some patients report reduced interest in alcohol on GLP-1 class drugs. Alcohol can worsen dehydration and nausea during titration.

Will my testosterone go back down if I stop the drug? If weight is regained after stopping, testosterone usually drops back toward baseline. Maintaining weight loss maintains the testosterone improvement.

Related guides

• Does Retatrutide Affect Libido? What the Data Show and What They Miss
• Does Retatrutide Affect Female Fertility? Reading the Signals That Exist
• Retatrutide for Men with Low Testosterone: What You Need to Know
• Retatrutide and Testosterone Levels in Men
• Can Retatrutide Cause Cancer? Thyroid Risk, Class Effects, and What We Don't Know
• Retatrutide for Bmi 30-35 Class 1 Obesity: What Research Shows

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
2. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology. 2013;168:829-843.
3. Esposito K, Giugliano F, Maiorino MI, Giugliano D. Dietary factors, Mediterranean diet and erectile dysfunction. Diabetes Care. 2011.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
6. Rosenstock J et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023.
7. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM. 2018.
8. Teede HJ et al. International Evidence-Based Guideline for the Assessment and Management of PCOS, 2023 Update.
9. Salamun V et al. Liraglutide increases IVF pregnancy rates in obese PCOS women. European Journal of Endocrinology. 2018.
10. American Urological Association. Erectile Dysfunction Guideline, 2024 Update.
11. Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity, 2024 Update.
12. FDA. Wegovy and Zepbound Prescribing Information.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not prescribe or dispense medications directly. Hormone-related care decisions, including testing, replacement therapy, and fertility planning, are made between the patient and the prescribing clinician.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are produced by state-licensed 503A compounding pharmacies in response to individual prescriptions. They are not FDA-approved and not interchangeable with branded products.

Investigational Drug Notice. Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or facilitate access to retatrutide. The hormone-related discussion on this page is inferred from phase 2 trial design, broader class data, and the established physiology of weight-loss-related hormonal change.

Results Disclaimer. Hormonal and libido responses to weight loss vary widely between individuals. Average effects in clinical trials may not predict any specific patient's response. Clinical decisions about hormone therapy should be based on individual labs, symptoms, and goals, not on group-level trial averages.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.